Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Resistant Hypertension: An Overview
Author(s): Giacomo Buso , Claudia Agabiti-Rosei , Matteo Lemoli , et al Added: 11 months ago

Prevention & Chronic Conditions
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 5 days ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
Evidence-Based Approaches to Optimising Treatment Outcome
Author(s): Javed Butler , Shelley Zieroth , Gianluigi Savarese Added: 8 months ago
Radcliffe Medical Education, is proud to bring to you this roundtable series which is designed to equip healthcare professionals with the knowledge and tools necessary to identify high-risk patients indicative of worsening HF and to implement effective management strategies. Watch Dr Javed Butler (Baylor Scott & White Health, Dallas, US); Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA)… View more

Heart Failure
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 11 months ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program
Author(s): Harriette Van Spall , Dike Bevis Ojji Added: 1 year ago
AHA 2023 — Investigator Dr Dike Bevis Ojji (University of Abuja, NG) talks with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) about the Hypertension Treatment in Nigeria Program (NCT04158154).The aim of this study (Washington University School of Medicine) and employing an interrupted time series design, is to assess the implementation and evaluation of a culturally- and… View more

Prevention & Chronic Conditions
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 10 months ago

Anticoagulation

Prevention & Chronic Conditions
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 1 year ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
HFA 23: APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis
Author(s): Marianna Fontana Added: 2 years ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383). APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1… View more

Heart Failure
Glucagon-Containing Dual and Triple Agonists For Obesity and MASH
Author(s): Scott Harris Added: 11 months ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure